|
Target | Agent | Type | Mechanism | Trial ID or reference |
|
Mitochondrial complex I and metformin ACC | Metformin | ESCC | Metformin can be used as an alternative therapy for chemotherapy- and radiotherapy-refractory esophageal squamous cell carcinoma by inducing cell apoptosis. | [83] |
| | ESCC | Metformin inhibited the growth and metastasis of ESCC. | [84] |
|
| Metformin with gemcitabine | OSCC | Metformin induces 5-Fu resistance by altering nucleotide metabolism in OSCC. | [85] |
|
| Metformin with cisplatin | ESCC | Metformin combined with chemotherapy can reverse cisplatin resistance by reducing intracellular glutathione levels. | [86] |
|
Natural alkaloid | Berberine | ESCC | By targeting and blocking miR-212, berberine effectively inhibits the invasion and metastasis of ESCC. | [87] |
| miR-18b-5p | ESCC | miR-18b-5p regulates de novo lipid synthesis by regulating FASN, ACC1, and SREBP1C and promotes ESCC tumorigenesis and progression. | [33] |
|
Nonsteroidal anti-inflammatory drugs (NSAIDs) | Acetylsalicylic acid (aspirin) | ESCC | Aspirin enhances the therapeutic efficacy of cisplatin in ESCC. | [88] |
| Aspirin + statins | OSCC | The combination of aspirin and statin is cost-effective in patients at high risk for progression to esophageal adenocarcinoma. | [89] |
|
HMG-CoA reductase (HMGCR) | Statins (e.g., simvastatin and atorvastatin) | OSCC | The use of statins is associated with a significantly lower incidence of OSCC. | [90] |
| | ESCC | Atorvastatin inhibits ESCC tumor growth in a PDX model by inhibiting the cAMP and Rap1 signaling pathways. | [91] |
|
Part of carnitine palmitoyltransferase 1 (CPT1) | Carnitine/organic cation transporter novel 2 + Oxaliplatin | ESCC | High expression of OCTN2 promotes the accumulation and cytotoxic activity of oxaliplatin in patients with esophageal cancer, resulting in a reduced risk of recurrence and prolonged survival in EC patients. | [92] |
|
Fatty acid synthase (FASN) | Orlistat (a pancreatic lipase inhibitor developed for obesity treatment), C75, a first-generation synthetic small-molecule inhibitor of FAS, C93, a second-generation small-molecular inhibitor with increased specificity. Previous efforts to treat xenograft cancers with C75 | Squamous carcinoma and adenocarcinoma of the esophagus, as well as cases of Barrett’s esophagus with varying levels of dysplasia | FAS is expressed at very high levels in esophageal cancer and growth of these cancers can be inhibited by C93. C75 inhibited OSCC proliferation | [39, 81] |
|
Diferuloylmethane | Curcumin | ESCC/OSCC | Curcumin has influences on FAS activity, FAO, and desaturation system. Curcumin may inhibit the proliferation and colony formation of EC according to dose and time. | [93, 94] |
|
Sterol regulatory element-binding proteins (SREBPs) | Fatostatin (4-hydroxytamoxifen, an active metabolite of tamoxifen) | ESCC | Fatostatin significantly inhibited tumorigenesis by downregulating SREBP1 and EMT markers. | [82] |
|
Estrogen receptor (ER) receptor | Natural estrogen (17b-estradiol) selective ER modulators (SERM) tamoxifen and raloxifene | OSCC and Barrett’s esophagus | Tamoxifen and raloxifene act as agonists of ER signaling, producing pro-apoptotic and growth-inhibitory effects. | [95] |
|
SQLE inhibitor | siRNA | ESCC | The siRNA significantly inhibited the proliferation and invasion of esophageal cancer cells by regulating the expression of cell cycle and EMT-related proteins. | [96, 97] |
|